Adeno-Associated Virus-Mediated RNAi against Mutant Alleles Attenuates Abnormal Calvarial Phenotypes in an Apert Syndrome Mouse Model

Twigg, 2015, A Genetic-Pathophysiological Framework for Craniosynostosis, Am. J. Hum. Genet., 97, 359, 10.1016/j.ajhg.2015.07.006 Azoury, 2017, Fibroblast growth factor receptor 2 (FGFR2) mutation related syndromic craniosynostosis, Int. J. Biol. Sci., 13, 1479, 10.7150/ijbs.22373 Hehr, 1999, Craniosynostosis syndromes: from genes to premature fusion of skull bones, Mol. Genet. Metab., 68, 139, 10.1006/mgme.1999.2915 Wilkie, 1995, Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome, Nat. Genet., 9, 165, 10.1038/ng0295-165 Oldridge, 1997, Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2, Hum. Mol. Genet., 6, 137, 10.1093/hmg/6.1.137 Chen, 2003, A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis, Bone, 33, 169, 10.1016/S8756-3282(03)00222-9 Wang, 2005, Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse, Development, 132, 3537, 10.1242/dev.01914 Yin, 2008, A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis, Bone, 42, 631, 10.1016/j.bone.2007.11.019 Wang, 2010, Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice, BMC Dev. Biol., 10, 22, 10.1186/1471-213X-10-22 Holmes, 2009, Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology, Dev. Biol., 328, 273, 10.1016/j.ydbio.2009.01.026 Du, 2010, Dynamic morphological changes in the skulls of mice mimicking human Apert syndrome resulting from gain-of-function mutation of FGFR2 (P253R), J. Anat., 217, 97 Luo, 2017, Deformed Skull Morphology Is Caused by the Combined Effects of the Maldevelopment of Calvarias, Cranial Base and Brain in FGFR2-P253R Mice Mimicking Human Apert Syndrome, Int. J. Biol. Sci., 13, 32, 10.7150/ijbs.16287 Aldridge, 2010, Brain phenotypes in two FGFR2 mouse models for Apert syndrome, Dev. Dyn., 239, 987, 10.1002/dvdy.22218 Martínez-Abadías, 2010, Beyond the closed suture in apert syndrome mouse models: evidence of primary effects of FGFR2 signaling on facial shape at birth, Dev. Dyn., 239, 3058, 10.1002/dvdy.22414 Nagata, 2011, The primary site of the acrocephalic feature in Apert Syndrome is a dwarf cranial base with accelerated chondrocytic differentiation due to aberrant activation of the FGFR2 signaling, Bone, 48, 847, 10.1016/j.bone.2010.11.014 Shukla, 2007, RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis, Nat. Genet., 39, 1145, 10.1038/ng2096 Breik, 2016, Apert syndrome: Surgical outcomes and perspectives, J. Craniomaxillofac. Surg., 44, 1238, 10.1016/j.jcms.2016.06.001 Kosty, 2015, Insights into the development of molecular therapies for craniosynostosis, Neurosurg. Focus, 38, E2, 10.3171/2015.2.FOCUS155 Morita, 2014, Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model, Dev. Dyn., 243, 560, 10.1002/dvdy.24099 Yokota, 2014, Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis, PLoS ONE, 9, e101693, 10.1371/journal.pone.0101693 Liang, 2015, Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy, Nat. Med., 21, 288, 10.1038/nm.3791 Jiang, 2013, Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy, Science, 342, 111, 10.1126/science.1236921 Bongianino, 2017, Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (RYR2), Circ. Res., 121, 525, 10.1161/CIRCRESAHA.117.310882 Perrimon, 2010, In vivo RNAi: today and tomorrow, Cold Spring Harb. Perspect. Biol., 2, a003640, 10.1101/cshperspect.a003640 Deng, 2014, Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies, Gene, 538, 217, 10.1016/j.gene.2013.12.019 Nguyen, 2008, RNAi therapeutics: an update on delivery, Curr. Opin. Mol. Ther., 10, 158 Zincarelli, 2008, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection, Mol. Ther., 16, 1073, 10.1038/mt.2008.76 Kotterman, 2014, Engineering adeno-associated viruses for clinical gene therapy, Nat. Rev. Genet., 15, 445, 10.1038/nrg3742 Valdmanis, 2017, Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond, Hum. Gene Ther., 28, 361, 10.1089/hum.2016.171 Luk, 2003, Adeno-associated virus-mediated bone morphogenetic protein-4 gene therapy for in vivo bone formation, Biochem. Biophys. Res. Commun., 308, 636, 10.1016/S0006-291X(03)01429-3 Gafni, 2004, Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system, Mol. Ther., 9, 587, 10.1016/j.ymthe.2003.12.009 Johnson, 2011, Craniosynostosis, Eur. J. Hum. Genet., 19, 369, 10.1038/ejhg.2010.235 Senarath-Yapa, 2012, Craniosynostosis: molecular pathways and future pharmacologic therapy, Organogenesis, 8, 103, 10.4161/org.23307 Lei, 2017, Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer, Int. J. Biol. Sci., 13, 1163, 10.7150/ijbs.20792 Larson, 2013, CRISPR interference (CRISPRi) for sequence-specific control of gene expression, Nat. Protoc., 8, 2180, 10.1038/nprot.2013.132 Rizk, 2017, Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran, Pharm. Genomics Pers. Med., 10, 267 Schwarz, 2006, Designing siRNA that distinguish between genes that differ by a single nucleotide, PLoS Genet., 2, e140, 10.1371/journal.pgen.0020140 Haley, 2004, Kinetic analysis of the RNAi enzyme complex, Nat. Struct. Mol. Biol., 11, 599, 10.1038/nsmb780 Nasu, 2009, Biological activation of bone-related biomaterials by recombinant adeno-associated virus vector, J. Orthop. Res., 27, 1162, 10.1002/jor.20860 Chen, 2003, Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors, Gene Ther., 10, 1345, 10.1038/sj.gt.3301999 Chen, 2004, Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats, Biochem. Biophys. Res. Commun., 317, 675, 10.1016/j.bbrc.2004.03.098 Schwenk, 1995, A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells, Nucleic Acids Res., 23, 5080, 10.1093/nar/23.24.5080 Garrett, 2003, Assessing bone formation using mouse calvarial organ cultures, Methods Mol. Med., 80, 183 Heuzé, 2014, Morphological comparison of the craniofacial phenotypes of mouse models expressing the Apert FGFR2 S252W mutation in neural crest- or mesoderm-derived tissues, Bone, 63, 101, 10.1016/j.bone.2014.03.003 Richtsmeier, 1990, Analysis of craniofacial growth in Crouzon syndrome using landmark data, J. Craniofac. Genet. Dev. Biol., 10, 39 Lele, 1995, Euclidean distance matrix analysis: confidence intervals for form and growth differences, Am. J. Phys. Anthropol., 98, 73, 10.1002/ajpa.1330980107 Richtsmeier, 2000, Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice, Dev. Dyn., 217, 137, 10.1002/(SICI)1097-0177(200002)217:2<137::AID-DVDY1>3.0.CO;2-N